NCT00587691 - Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2002

Primary Completion Date

June 30, 2007

Study Completion Date

December 31, 2008

Conditions

Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary Progressive

Interventions

BIOLOGICAL

Tovaxin Autologous T Cell Vaccine

"Primary Series (x1): 4 subcutaneous injections (wks 0, 4, 12 and 20 with 52 week evaluable period.~Retreatment Series (x3): 3 subcutaneous injections (wks 0, 4, and 8) with 26-week evaluable periods.~Retreatment Series (x3): 5 subcutaneous injections (wks 0, 8, 26, 24 and 32) with 52-week evaluable periods."

Trial Locations (2)

77030

Baylor College of Medicine, Houston

77401

Bellaire Neurology, Bellaire